INTANGIBLE ASSETS AND GOODWILL (Tables)
|
3 Months Ended |
Mar. 31, 2026 |
| Goodwill and Intangible Assets Disclosure [Abstract] |
|
| Schedule of indefinite-lived intangible assets |
The major components of intangible assets consist of: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | March 31, 2026 | | December 31, 2025 | | (in millions) | Gross Carrying Amount | | Accumulated Amortization and Impairments | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization and Impairments | | Net Carrying Amount | Finite-lived intangible assets: | | | | | | | | | | | | | Product brands | $ | 4,382 | | | $ | (3,056) | | | $ | 1,326 | | | $ | 4,441 | | | $ | (3,064) | | | $ | 1,377 | | | Corporate brands | 102 | | | (29) | | | 73 | | | 102 | | | (26) | | | 76 | | | Product rights/patents | 999 | | | (988) | | | 11 | | | 999 | | | (988) | | | 11 | | | Other | 87 | | | (69) | | | 18 | | | 87 | | | (68) | | | 19 | | | Total finite-lived intangible assets | 5,570 | | | (4,142) | | | 1,428 | | | 5,629 | | | (4,146) | | | 1,483 | | | Acquired in-process research and development intangible asset | 100 | | | — | | | 100 | | | 100 | | | — | | | 100 | | | B&L Trademark | 1,698 | | | — | | | 1,698 | | | 1,698 | | | — | | | 1,698 | | | $ | 7,368 | | | $ | (4,142) | | | $ | 3,226 | | | $ | 7,427 | | | $ | (4,146) | | | $ | 3,281 | |
|
| Schedule of finite-lived intangible assets |
The major components of intangible assets consist of: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | March 31, 2026 | | December 31, 2025 | | (in millions) | Gross Carrying Amount | | Accumulated Amortization and Impairments | | Net Carrying Amount | | Gross Carrying Amount | | Accumulated Amortization and Impairments | | Net Carrying Amount | Finite-lived intangible assets: | | | | | | | | | | | | | Product brands | $ | 4,382 | | | $ | (3,056) | | | $ | 1,326 | | | $ | 4,441 | | | $ | (3,064) | | | $ | 1,377 | | | Corporate brands | 102 | | | (29) | | | 73 | | | 102 | | | (26) | | | 76 | | | Product rights/patents | 999 | | | (988) | | | 11 | | | 999 | | | (988) | | | 11 | | | Other | 87 | | | (69) | | | 18 | | | 87 | | | (68) | | | 19 | | | Total finite-lived intangible assets | 5,570 | | | (4,142) | | | 1,428 | | | 5,629 | | | (4,146) | | | 1,483 | | | Acquired in-process research and development intangible asset | 100 | | | — | | | 100 | | | 100 | | | — | | | 100 | | | B&L Trademark | 1,698 | | | — | | | 1,698 | | | 1,698 | | | — | | | 1,698 | | | $ | 7,368 | | | $ | (4,142) | | | $ | 3,226 | | | $ | 7,427 | | | $ | (4,146) | | | $ | 3,281 | |
|
| Schedule of estimated aggregate amortization expense for each of the five succeeding years |
Estimated amortization expense of finite-lived intangible assets for the remainder of 2026 and the five succeeding years ending December 31 and thereafter are as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (in millions) | | Remainder of 2026 | | 2027 | | 2028 | | 2029 | | 2030 | | 2031 | | Thereafter | | Total | | Amortization | | $ | 168 | | | $ | 222 | | | $ | 221 | | | $ | 219 | | | $ | 216 | | | $ | 215 | | | $ | 167 | | | $ | 1,428 | |
|
| Schedule of changes in the carrying amount of goodwill |
The changes in the carrying amounts of goodwill during the three months ended March 31, 2026 and the year ended December 31, 2025 were as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | (in millions) | | | | Vision Care | | Pharmaceuticals | | Surgical | | Total | | Balance, January 1, 2025 | | | | $ | 3,529 | | | $ | 644 | | | $ | 350 | | | $ | 4,523 | | | Acquisitions (Note 5) | | | | — | | | — | | | 97 | | | 97 | | | Foreign exchange and other | | | | 26 | | | 100 | | | 12 | | | 138 | | | Balance, December 31, 2025 | | | | 3,555 | | | 744 | | | 459 | | | 4,758 | | | | | | | | | | | | | | | | | | | | | | | | | Foreign exchange and other | | | | (5) | | | (13) | | | (3) | | | (21) | | Balance, March 31, 2026 | | | | $ | 3,550 | | | $ | 731 | | | $ | 456 | | | $ | 4,737 | |
|